# innOWL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innowl

- Industry: Pharmaceuticals
- Headquarters: Seoul, South Korea
- Latest round: Seed (Feb 4, 2026)
- Investors on record: 2

## About

Based in Seoul, South Korea, founded in 2025, innOWL operates as a company that develops a precision diagnostic system for atopic dermatitis that uses a minimally invasive microneedle patch, RNA transcriptome analysis, and artificial intelligence–based subtype classification. In February 2026, innOWL raised an amount of seed funding from investors CNT Tech and DB Capital.

The company is developing a precision diagnosis system for atopic dermatitis. Its technology combines microneedle patches, RNA analytics, and AI based modeling to support data driven diagnostic processes. The approach is designed to be minimally invasive while enabling detailed biological analysis. Clinical validation is a key component of product development, with trials currently underway to assess performance and applicability in medical settings.

The company plan to use the February 2026 funding to speed up the collection of clinical data, enhance its artificial intelligence diagnostic model, and begin expanding its business in full.

## Funding rounds

- Seed, Feb 4, 2026 — DB Capital, CNT Tech

## Investors

- DB Capital (https://capitalatlas.ai/funds/db-capital) — Seed
- CNT Tech (https://capitalatlas.ai/funds/cnt-tech) — Seed